贝普奈单抗在阿尔茨海默病前驱期至轻度患者中的安全性、耐受性和疗效:一项随机、双盲、安慰剂对照的2期试验
这项在101个门诊中心开展的2期试验将466例阿尔茨海默病前驱期至轻度患者随机分配至贝普奈单抗45 mg/kg、90 mg/kg或安慰剂组,每4周静脉给药一次持续76周。主要终点CDR-SB总分变化未达统计学显著,安全性可接受,未发现治疗相关神经炎症信号。
要点
- 贝普奈单抗90 mg/kg组CDR-SB变化与安慰剂差异为0·34(95%CI -0·09至0·78,p=0·12),未达统计学显著。
- 贝普奈单抗45 mg/kg组CDR-SB变化与安慰剂差异为0·04(95%CI -0·40至0·47,p=0·87)。
- 治疗中出现的不良事件频率与安慰剂组相似,未发现治疗相关神经炎症安全信号。
核心结论
- 贝普奈单抗治疗具有可接受的安全性特征,但主要终点未达到。
- tau PET和14项阿尔茨海默病评估量表-认知子量表方面有利于贝普奈单抗的假设生成性差异,应在以tau PET为终点并分层的研究中前瞻性检验。
研究设计与样本
- 这项双盲、安慰剂对照的2期试验在欧洲八国、加拿大和美国的101个门诊中心招募参与者。
- 参与者年龄50-80岁,患阿尔茨海默病前驱期至轻度,按1:1:1随机分配至静脉贝普奈单抗45 mg/kg、90 mg/kg或安慰剂组,每4周给药一次持续76周。
- 随机分层因素为诊断、载脂蛋白E ɛ4携带状态和症状性治疗使用。
- 主要终点为从基线至第80周CDR-SB总分变化;疗效分析纳入全分析集,安全性分析纳入所有接受至少部分剂量者。
主要发现
- 2021年8月24日至2022年10月25日,466例参与者被随机分配至贝普奈单抗45 mg/kg组(n=154)、90 mg/kg组(n=155)或安慰剂组(n=157),分布于85个中心。
- 中位年龄为72·0岁(IQR 66·0-76·0),女性259例(56%),男性207例(44%)。
- 全分析集共460例:贝普奈单抗45 mg/kg组(n=152)、90 mg/kg组(n=152)、安慰剂组(n=156)。
- 从基线至第80周CDR-SB总分最小二乘均值变化:贝普奈单抗90 mg/kg组为2·15,45 mg/kg组为1·85,安慰剂组为1·81;与安慰剂差异分别为0·34(95%CI -0·09至0·78,p=0·12;80%CI 0·06至0·63)和0·04(95%CI -0·40至0·47,p=0·87;80%CI -0·25至0·32)。
- 治疗中出现的不良事件频率:贝普奈单抗45 mg/kg组139例(91%),90 mg/kg组140例(91%),安慰剂组142例(90%)。
关键数值与推荐
- 主要终点CDR-SB总分从基线至第80周变化:贝普奈单抗90 mg/kg组与安慰剂差异为0·34(95%CI -0·09至0·78,p=0·12;80%CI 0·06至0·63)。
- 贝普奈单抗45 mg/kg组与安慰剂差异为0·04(95%CI -0·40至0·47,p=0·87;80%CI -0·25至0·32)。
- 未发现治疗相关神经炎症安全信号(临床或脑MRI)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要终点未达到。
- 原文结论指出,tau PET和14项阿尔茨海默病评估量表-认知子量表的差异为假设生成性,应在前瞻性试验中检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tau aggregation is a defining feature of the pathophysiology of Alzheimer's disease and an appealing therapeutic target, yet tau-directed antibodies tested to date-primarily targeting N-terminal epitopes-have failed to slow tau progression or cognitive decline. Bepranemab targets the tau mid-region, predicted in cell-based assays to more effectively block neuron-to-neuron tau spread than anti-tau antibodies targeting the N-terminus. We aimed to investigate the safety and efficacy of bepranemab in slowing progression of tau pathology and clinical decline in people with prodromal-to-mild Alzheimer's disease. METHODS: This double-blind, placebo-controlled, phase 2 trial recruited participants across 101 outpatient sites in Europe (eight countries), Canada, and the USA. Participants (aged 50-80 years) with prodromal-to-mild Alzheimer's disease were randomly assigned 1:1:1 (using an interactive response system) to intravenous bepranemab 45 mg/kg, bepranemab 90 mg/kg, or placebo (every 4 weeks for 76 weeks), stratified by diagnosis, apolipoprotein E ɛ4 carrier status, and symptomatic treatment use. The primary endpoint was change from baseline to week 80 in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) total score. Efficacy was assessed in the full analysis set (ie, all randomly assigned participants who received at least a partial dose of trial medication and had at least one valid post-baseline clinic visit and efficacy assessment). Safety was assessed in all randomly assigned participants who received at least a partial dose of the trial medication. No imputation was done for missing data. The trial is registered at ClinicalTrials.gov (NCT04867616) and is complete. FINDINGS: Between Aug 24, 2021, and Oct 25, 2022, 466 participants were randomly assigned to bepranemab 45 mg/kg (n=154), bepranemab 90 mg/kg (n=155), or placebo (n=157) at 85 sites. Median age was 72·0 years (IQR 66·0-76·0), 259 (56%) were female, and 207 (44%) were male. In total, 460 participants were included in the full analysis set: bepranemab 45 mg/kg (n=152), bepranemab 90 mg/kg (n=152), and placebo (n=156). Least-squares mean CDR-SB total score change from baseline to week 80 was 2·15 in the bepranemab 90 mg/kg group and 1·85 in the bepranemab 45 mg/kg group versus 1·81 in the placebo group, with differences versus placebo of 0·34 (95% CI -0·09 to 0·78, p=0·12; 80% CI 0·06 to 0·63) for the bepranemab 90 mg/kg group and 0·04 (-0·40 to 0·47, p=0·87; -0·25 to 0·32) for the bepranemab 45 mg/kg group. Frequency of treatment-emergent adverse events with bepranemab was similar to the placebo group (139 [91%] with bepranemab 45 mg/kg, 140 [91%] with bepranemab 90 mg/kg, and 142 [90%] with placebo); no treatment-related neuroinflammatory safety signals were identified clinically or on brain MRI scans. There were adverse events leading to death in four (1%) participants in the combined bepranemab groups and six (4%) in the placebo group; none were considered related to the trial treatment. INTERPRETATION: Treatment with bepranemab was associated with an acceptable safety profile. However, the primary endpoint was not met. Hypothesis-generating differences favouring bepranemab in tau PET and 14-item Alzheimer's Disease Assessment Scale-Cognitive Subscale should be tested prospectively in trials powered for tau PET outcomes and stratified by baseline tau burden and apolipoprotein E ɛ4 status. FUNDING: UCB.
引用
- Barton ME, Byrnes W, van den Steen B, et al. Safety, tolerability, and efficacy of bepranemab in people living with prodromal-to-mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2026. PMID: 43008775. doi:10.1016/S1474-4422(26)00357-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。